Clinical Trial Update: Effect of Guselkumab on Cardiovascular Risk Surrogate Markers in Participants With Moderate to Severe Plaque Psoriasis [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluated guselkumab for effects on cardiovascular risk surrogate markers in adults with moderate-to-severe plaque psoriasis; the study was term…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• TREMFYA (guselkumab)

Snippet

Sponsor: Janssen-Cilag Ltd. | Conditions: Psoriasis | Phase 4 | Status: TERMINATED | Results posted: 2025-01-27